Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7734069 | 0.90 | LMNA (0.46) | CES1HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL29249471 | 0.83 | MLYCD (0.50) | CES1HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL27498230 | 0.82 | SMN1; SMN2 (0.47) | PPIDLMNA | |
| SCHEMBL6317990 | 0.80 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11176841 | 0.79 | THRB (0.48) | ALDH1A1TSHRLMNATHRBIDO1 | |
| SCHEMBL6429495 | 0.79 | THRB (0.48) | ALDH1A1TSHRLMNATHRBIDO1 | |
| SCHEMBL3507989 | 0.79 | TRPV1 (0.45) | HDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL21925540 | 0.76 | SMN1; SMN2 (0.55) | ALDH1A1MAPTLMNA | |
| SCHEMBL2542923 | 0.76 | CYP1A2 (0.47) | MAPTTSHRLMNATHRBIDO1 | |
| SCHEMBL21611670 | 0.76 | STING1 (0.54) | PPIDALDH1A1TSHRLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333641-B | Enhanced fluorescent probe for tetrazine bio-orthogonal labeling and synthesis thereof | 中国科学院大连化学物理研究所 | 2022-05-31 | — | — | CN | claimed |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| CN-106458952-B | Heterocycle sulfamide derivatives and drug containing the heterocycle sulfamide derivatives | EA制药株式会社 | 2019-09-27 | — | — | CN | disclosed |
| EP-2990405-B1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2019-07-17 | — | — | EP | disclosed |
| CN-105189479-B | Deuterated diaminopyrimidine compounds and the pharmaceutical composition comprising the compound | 苏州泽璟生物制药有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2018-02-15 | — | — | US | disclosed |
| US-9809572-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| CN-106458952-A | Heterocyclic sulfonamide derivative and medicine comprising same | EA制药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
| EP-2990405-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | Suzhou Zelgen Biopharmaceuticals Co. Ltd. (CN) | 2016-03-02 | — | — | EP | disclosed |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | ZHOU JIACHENG | 2005-11-03 | — | — | US | disclosed |
| US-6919451-B2 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1467984-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6465656-B2 | ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-15 | — | — | US | disclosed |
| EP-1222172-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| US-6329527-B1 | ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001029006-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, PDCD1 | CES1 4185/4885HDAC3 2720/4885HDAC4 2461/4885 |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | TFPI, SERPINC1, F11 | CES1 161/4885HDAC3 298/4885HDAC4 836/4885 |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | DCK, DPYD, BRAF | CES1 4179/4885HDAC3 2729/4885HDAC4 2301/4885 |
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, BRAF | CES1 4179/4885HDAC3 2729/4885HDAC4 2301/4885 |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | TFPI, TFPI2, F2 | CES1 392/4885HDAC3 561/4885HDAC4 426/4885 |
| US-20050245566-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | F2, TFPI, TFPI2 | CES1 1022/4885HDAC3 430/4885HDAC4 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.